Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Efsubaglutide alfa (supaglutide)

Efsubaglutide alfa (supaglutide)

GLP-1 · s.c. weekly · Yinnuo (Innogen)

Data cut 12 November 2026 · page built 16 November 2026 · 5 trial arms · 3 trials with results · 4 registered trials · see on the pipeline board

Summary

Also known as
Yinnuo / Innogen
Mechanism
GLP-1
Route
s.c. weekly
Company
Yinnuo (Innogen)
Highest development stage
approved
Status (as of data cut)
Approved in China for T2D (January 2025); obesity phase 2b ENLIGHT positive; obesity phase 3 topline expected end-2026 verify
Next milestone
Obesity phase 3

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity2 phase 3 ongoingPhase 2b ENLIGHT positive; phase 3 topline expected end-2026
T2D4 approved / in labelNMPA (China), January 2025Innogen interim report (HKEX, Aug 2026)
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH0 no data
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
ENLIGHT Phase IIb (NCT06921486)20 mg QWobesity china18200——−10.6 %
estimand not specified
———————press release
ENLIGHT Phase IIb (NCT06921486)20 mg Q2Wobesity china18200——−9.7 %
estimand not specified
———————press release
SUPER 2 (NCT04998032), phase 2b stage1 mg QWt2d china12120——−1.1——————press release
SUPER 2 (NCT04998032), phase 2b stage3 mg QWt2d china12120——−1.4——————press release
SUPER 2 (NCT04998032), phase 3 stage3 mg QWt2d china24171——−1.8 vs −0.7——7.6 vs 4.09.9 vs 1.7——press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (7)
  • 20 mg QW · weight_unsp · press release
    Efsubaglutide α significantly reduced the weight of participants, with reductions of 10.58% and 9.70% in the QW and Q2W groups, respectively.
  • 20 mg Q2W · weight_unsp · press release
    Efsubaglutide α significantly reduced the weight of participants, with reductions of 10.58% and 9.70% in the QW and Q2W groups, respectively.
  • 3 mg QW · hba1c · publication
    At week 24 in phase 3, HbA1c decreased by 1.80% with Efsubaglutide 3 mg versus 0.74% with placebo
  • 3 mg QW · vomiting · publication
    including diarrhoea (21.6% vs. 3.5%), vomiting (9.9% vs. 1.7%), nausea (7.6% vs. 4.0%)
  • 3 mg QW · nausea · publication
    including diarrhoea (21.6% vs. 3.5%), vomiting (9.9% vs. 1.7%), nausea (7.6% vs. 4.0%)
  • 1 mg QW · hba1c · publication
    At week 12 in phase 2b, HbA1c decreased by 1.10% with 1 mg and 1.43% with 3 mg
  • 3 mg QW · hba1c · publication
    At week 12 in phase 2b, HbA1c decreased by 1.10% with 1 mg and 1.43% with 3 mg

Registered trials (4)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
NCT06900075
Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients
T2DPhase 3not yet recruiting2025-07 → 2026-0188not yet recruitingNCT06900075
ENLIGHT
The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)
ObesityPhase 3active not recruiting2025-03 → 2026-081003active not recruitingNCT06921486
SUPER-2
A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients On Metformin Treatment(SUPER-2)
T2DPhase 3completed2021-10 → 2023-06620Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT04998032
SUPER-1
A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients(SUPER-1)
T2DPhase 3completed2021-08 → 2023-06547Completed; results not in the atlas yetNCT04994288

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Efsubaglutide alfa (supaglutide). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/efsubaglutide-alfa/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.